Pharmacological Enhancement for Nocturnal Incontinence in Orthotopic Bladder Substitute

• Status: Completed
• Trial end date: 2020-03-01
• Target enrollment: 0
• Participant gender: Male

Summary

In this randomised trial, we hypothesised that mebeverine could enhance nocturnal continenece of Orthotopic Bladder Substitute (OBS) patients by decreasing the frequency and reduce maximum amplitude of uninhibited contractions of OBS ileum, and consequently it would increase the OBS capacity

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Mansoura University
• Treatments: Mebeverine

Criteria

Inclusion Criteria:

• nocturnal enuresis

Exclusion Criteria:

• daytime incontinence

• Orthotopic Bladder Substitute (OBS) reconstruction surgery ≤2 years

• chronic kidney disease

• local tumor recurrence

• adjuvant chemotherapy and/or radiotherapy

• chronic retention requiring use of clean intermittent catheterization or indwelling urethral catheterization

• suspected or known narrow-angle glaucoma

• sensitivity to mebeverine.